Tumour-derived PGD2 and NKp30-B7H6 Engagement Drives an Immunosuppressive ILC2-MDSC Axis

Group 2 innate lymphoid cells (ILC2s) are involved in human diseases, such as allergy, atopic dermatitis and nasal polyposis, but their function in human cancer remains unclear. Here we show that, in acute promyelocytic leukaemia (APL), ILC2s are increased and hyper-activated through the interaction of CRTH2 and NKp30 with elevated tumour-derived PGD2 and B7H6, respectively. ILC2s, in turn, activate monocytic myeloid-derived suppressor cells (M-MDSCs) via IL-13 secretion. Upon treating APL with all-trans retinoic acid and achieving complete remission, the levels of PGD2, NKp30, ILC2s, IL-13 and M-MDSCs are restored. Similarly, disruption of this tumour immunosuppressive axis by specifically blocking PGD2, IL-13 and NKp30 partially restores ILC2 and M-MDSC levels and results in increased survival. Thus, using APL as a model, we uncover a tolerogenic pathway that may represent a relevant immunosuppressive, therapeutic targetable, mechanism operating in various human tumour types, as supported by our observations in prostate cancer.Group 2 innate lymphoid cells (ILC2s) modulate inflammatory and allergic responses, but their function in cancer immunity is still unclear. Here the authors show that, in acute promyelocytic leukaemia, tumour-activated ILC2s secrete IL-13 to induce myeloid-derived suppressor cells and support tumour growth.

Citing Articles

The Recruitment and Immune Suppression Mechanisms of Myeloid-Derived Suppressor Cells and Their Impact on Bone Metastatic Cancer.

Li C, Xue Y, Yinwang E, Ye Z Cancer Rep (Hoboken). 2025; 8(2):e70044.

PMID: 39947253 PMC: 11825175. DOI: 10.1002/cnr2.70044.

Infiltration of innate and adoptive lymphoid cells in 4T1 and MC4-L2 breast cancer models.

Rasooli Tehrani R, Asgarian-Omran H, Taghiloo S, Valadan R, Azizi S, Ajami A Iran J Basic Med Sci. 2025; 28(1):63-71.

PMID: 39877637 PMC: 11771339. DOI: 10.22038/ijbms.2024.80535.17434.

Multiple Myeloma Cells Shift the Fate of Cytolytic ILC2s Towards TIGIT-Mediated Cell Death.

Drommi F, Calabro A, Pezzino G, Vento G, Freni J, Costa G Cancers (Basel). 2025; 17(2.

PMID: 39858045 PMC: 11763689. DOI: 10.3390/cancers17020263.

Adaptive immune cells antagonize ILC2 homeostasis via SLAMF3 and SLAMF5.

Wang Y, Li D, Liu Y, Chen S, Dong Z Sci Adv. 2025; 11(2):eadp9894.

PMID: 39792675 PMC: 11721569. DOI: 10.1126/sciadv.adp9894.

N-methyladenosine and its epitranscriptomic effects on hematopoietic stem cell regulation and leukemogenesis.

Chang K, Shiau L, Lin S, Cheong H, Wang C, Ma C Mol Med. 2024; 30(1):196.

PMID: 39497033 PMC: 11536562. DOI: 10.1186/s10020-024-00965-x.

References

Halim T, Hwang Y, Scanlon S, Zaghouani H, Garbi N, Fallon P . Group 2 innate lymphoid cells license dendritic cells to potentiate memory TH2 cell responses. Nat Immunol. 2015; 17(1):57-64. PMC: 4685755. DOI: 10.1038/ni.3294. View

Kim J, Kim W, Moon U, Kim H, Choi H, Sin J . Intratumorally Establishing Type 2 Innate Lymphoid Cells Blocks Tumor Growth. J Immunol. 2016; 196(5):2410-23. DOI: 10.4049/jimmunol.1501730. View

Munneke J, Bjorklund A, Mjosberg J, Garming-Legert K, Bernink J, Blom B . Activated innate lymphoid cells are associated with a reduced susceptibility to graft-versus-host disease. Blood. 2014; 124(5):812-21. DOI: 10.1182/blood-2013-11-536888. View

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

Spencer S, Wilhelm C, Yang Q, Hall J, Bouladoux N, Boyd A . Adaptation of innate lymphoid cells to a micronutrient deficiency promotes type 2 barrier immunity. Science. 2014; 343(6169):432-7. PMC: 4313730. DOI: 10.1126/science.1247606. View

Molina M, Lemoine M, Frazier M, Sinicrope F . Increased cyclooxygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res. 1999; 59(17):4356-62. View

Wong S, Walker J, Jolin H, Drynan L, Hams E, Camelo A . Transcription factor RORα is critical for nuocyte development. Nat Immunol. 2012; 13(3):229-36. PMC: 3343633. DOI: 10.1038/ni.2208. View

Ailles L, Gerhard B, Kawagoe H, Hogge D . Growth characteristics of acute myelogenous leukemia progenitors that initiate malignant hematopoiesis in nonobese diabetic/severe combined immunodeficient mice. Blood. 1999; 94(5):1761-72. View

Gabitass R, Annels N, Stocken D, Pandha H, Middleton G . Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother. 2011; 60(10):1419-30. PMC: 3176406. DOI: 10.1007/s00262-011-1028-0. View

10.

Robinson M, McCarthy D, Smyth G . edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2009; 26(1):139-40. PMC: 2796818. DOI: 10.1093/bioinformatics/btp616. View

11.

Salimi M, Xue L, Jolin H, Hardman C, Cousins D, McKenzie A . Group 2 Innate Lymphoid Cells Express Functional NKp30 Receptor Inducing Type 2 Cytokine Production. J Immunol. 2015; 196(1):45-54. PMC: 4913864. DOI: 10.4049/jimmunol.1501102. View

12.

Oliphant C, Hwang Y, Walker J, Salimi M, Wong S, Brewer J . MHCII-mediated dialog between group 2 innate lymphoid cells and CD4(+) T cells potentiates type 2 immunity and promotes parasitic helminth expulsion. Immunity. 2014; 41(2):283-95. PMC: 4148706. DOI: 10.1016/j.immuni.2014.06.016. View

13.

Carrega P, Loiacono F, Di Carlo E, Scaramuccia A, Mora M, Conte R . NCR(+)ILC3 concentrate in human lung cancer and associate with intratumoral lymphoid structures. Nat Commun. 2015; 6:8280. DOI: 10.1038/ncomms9280. View

14.

Trabanelli S, Curti A, Lecciso M, Salome B, Riether C, Ochsenbein A . CD127+ innate lymphoid cells are dysregulated in treatment naïve acute myeloid leukemia patients at diagnosis. Haematologica. 2015; 100(7):e257-60. PMC: 4486236. DOI: 10.3324/haematol.2014.119602. View

15.

Brown D, Kogan S, Lagasse E, Weissman I, Alcalay M, Pelicci P . A PMLRARalpha transgene initiates murine acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 1997; 94(6):2551-6. PMC: 20126. DOI: 10.1073/pnas.94.6.2551. View

16.

Duffin R, OConnor R, Crittenden S, Forster T, Yu C, Zheng X . Prostaglandin E₂ constrains systemic inflammation through an innate lymphoid cell-IL-22 axis. Science. 2016; 351(6279):1333-8. PMC: 4841390. DOI: 10.1126/science.aad9903. View

17.

Nasr R, Guillemin M, Ferhi O, Soilihi H, Peres L, Berthier C . Eradication of acute promyelocytic leukemia-initiating cells through PML-RARA degradation. Nat Med. 2008; 14(12):1333-42. DOI: 10.1038/nm.1891. View

18.

Bernink J, Germar K, Spits H . The role of ILC2 in pathology of type 2 inflammatory diseases. Curr Opin Immunol. 2014; 31:115-20. DOI: 10.1016/j.coi.2014.10.007. View

19.

Bronte V, Brandau S, Chen S, Colombo M, Frey A, Greten T . Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards. Nat Commun. 2016; 7:12150. PMC: 4935811. DOI: 10.1038/ncomms12150. View

20.

Sonnenberg G, Artis D . Innate lymphoid cells in the initiation, regulation and resolution of inflammation. Nat Med. 2015; 21(7):698-708. PMC: 4869856. DOI: 10.1038/nm.3892. View